Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Market, reach, potential and growth of GMP laminins in NA

Reference number
Coordinator BioLamina AB
Funding from Vinnova SEK 120 612
Project duration June 2016 - December 2016
Status Completed

Purpose and goal

1) understand the market for clinical grade products better 2) identify customers in detail to understand their needs 3) make proper product pricing, offering and USPs All above achieved du to the detailed business plan conceived during this project.

Expected results and effects

BioLamina aims to enter the more potent clinical market space. With this project BioLamina has generated an executable business plan for the introduction of GMP laminins on the American market.

Planned approach and implementation

To assess the clinical market in the U.S, 155 primary research interviews were performed with current and potential customers, current and potential competitors, industry experts and employees to help inform the recommendations. In addition, secondary research was conducted which was substantiated with another round or interviews primarily with regulatory consultants.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2016-02918

Page statistics